MedTrace Logo

Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

NCT01700257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1361

Last updated 2020-12-31

No results posted yet for this study

Summary

Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.

Conditions

  • High Risk of Developing Lung Cancer

Interventions

RADIATION

CT scan & Early CDT Lung test

OTHER

CT scan & Early CDT Lung test

Sponsors & Collaborators

  • National Jewish Health

    lead OTHER

Principal Investigators

  • James R Jett, MD · National Jewish Health

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2020-12-07
Completion
2020-12-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01700257 on ClinicalTrials.gov